- Home
- RMT vs RIGL Comparison
RMT vs RIGL Comparison
Compare RMT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMT
- RIGL
- Stock Information
- Founded
- RMT 1993
- RIGL 1996
- Country
- RMT United States
- RIGL United States
- Employees
- RMT N/A
- RIGL N/A
- Industry
- RMT Investment Managers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RMT Finance
- RIGL Health Care
- Exchange
- RMT Nasdaq
- RIGL Nasdaq
- Market Cap
- RMT 491.1M
- RIGL 486.4M
- IPO Year
- RMT N/A
- RIGL 2000
- Fundamental
- Price
- RMT $10.07
- RIGL $20.13
- Analyst Decision
- RMT
- RIGL Buy
- Analyst Count
- RMT 0
- RIGL 5
- Target Price
- RMT N/A
- RIGL $34.80
- AVG Volume (30 Days)
- RMT 111.5K
- RIGL 344.2K
- Earning Date
- RMT 01-01-0001
- RIGL 03-04-2025
- Dividend Yield
- RMT 7.37%
- RIGL N/A
- EPS Growth
- RMT N/A
- RIGL N/A
- EPS
- RMT 1.49
- RIGL 0.22
- Revenue
- RMT N/A
- RIGL $157,374,000.00
- Revenue This Year
- RMT N/A
- RIGL $48.98
- Revenue Next Year
- RMT N/A
- RIGL $14.43
- P/E Ratio
- RMT $6.18
- RIGL $90.91
- Revenue Growth
- RMT N/A
- RIGL 21.65
- 52 Week Low
- RMT $7.67
- RIGL $7.48
- 52 Week High
- RMT $9.51
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- RMT 58.07
- RIGL 58.75
- Support Level
- RMT $9.55
- RIGL $15.50
- Resistance Level
- RMT $10.07
- RIGL $18.25
- Average True Range (ATR)
- RMT 0.17
- RIGL 1.28
- MACD
- RMT 0.04
- RIGL 0.43
- Stochastic Oscillator
- RMT 89.66
- RIGL 92.32
About RMT Royce Micro-Cap Trust Inc.
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector including auto components, automobiles, diversified consumer services, hotels, restaurants and leisure, household durables, internet and catalog retail, leisure products, media, multiline retail, textiles, apparels, and luxury goods, Consumer staples sector including beverages, food, and staples retailing, food products, and personal products, Energy sector including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors including healthcare, financials, industrials, IT, telecommunications, and materials.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.